TY - JOUR
T1 - The anticoagulant treatment for sepsis induced disseminated intravascular coagulation; network meta-analysis
AU - Yatabe, Tomoaki
AU - Inoue, Shigeaki
AU - Sakamoto, So
AU - Sumi, Yuka
AU - Nishida, Osamu
AU - Hayashida, Kei
AU - Hara, Yoshitaka
AU - Fukuda, Tatsuma
AU - Matsushima, Asako
AU - Matsuda, Akihisa
AU - Yasuda, Hideto
AU - Yamashita, Kazuto
AU - Egi, Moritoki
N1 - Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/11
Y1 - 2018/11
N2 - Introduction: The benefits and harm caused by anticoagulant treatments for sepsis induced disseminated intravascular coagulation (DIC) remain unclear. Therefore, we performed a network meta-analysis to assess the effect of available anticoagulant treatments on patient mortality, DIC resolution and the incidence of bleeding complication in patients with septic DIC. Materials and methods: We considered all studies from four recent systematic reviews and searched the PubMed, MEDLINE, and Cochrane databases for other studies that investigated anticoagulant treatment for septic DIC using antithrombin, thrombomodulin, heparin, or protease inhibitors in adult critically ill patients. These four anticoagulants and placebo were compared. The primary outcome in this study was patient mortality, and the secondary outcomes were the DIC resolution rate and incidence of bleeding complications. Results: The network meta-analysis included 1340 patients from nine studies. There were no significant differences in the risks of mortality and bleeding complications among all direct comparisons and the network meta-analysis. Using a placebo was associated with a significantly lower rate of DIC resolution, compared to antithrombin in the direct comparison (odds ratio [OR]: 0.20, 95% credible interval [95% CrI]: 0.046–0.81) and in the network meta-analysis (OR: 0.20, 95% CrI: 0.043–0.84). Conclusions: Our study revealed no significant differences in the risks for mortality and bleeding complications when a placebo and all four anticoagulants were compared in septic DIC patients. The results also indicated that antithrombin was associated with a five-fold higher likelihood of DIC resolution, compared to placebo.
AB - Introduction: The benefits and harm caused by anticoagulant treatments for sepsis induced disseminated intravascular coagulation (DIC) remain unclear. Therefore, we performed a network meta-analysis to assess the effect of available anticoagulant treatments on patient mortality, DIC resolution and the incidence of bleeding complication in patients with septic DIC. Materials and methods: We considered all studies from four recent systematic reviews and searched the PubMed, MEDLINE, and Cochrane databases for other studies that investigated anticoagulant treatment for septic DIC using antithrombin, thrombomodulin, heparin, or protease inhibitors in adult critically ill patients. These four anticoagulants and placebo were compared. The primary outcome in this study was patient mortality, and the secondary outcomes were the DIC resolution rate and incidence of bleeding complications. Results: The network meta-analysis included 1340 patients from nine studies. There were no significant differences in the risks of mortality and bleeding complications among all direct comparisons and the network meta-analysis. Using a placebo was associated with a significantly lower rate of DIC resolution, compared to antithrombin in the direct comparison (odds ratio [OR]: 0.20, 95% credible interval [95% CrI]: 0.046–0.81) and in the network meta-analysis (OR: 0.20, 95% CrI: 0.043–0.84). Conclusions: Our study revealed no significant differences in the risks for mortality and bleeding complications when a placebo and all four anticoagulants were compared in septic DIC patients. The results also indicated that antithrombin was associated with a five-fold higher likelihood of DIC resolution, compared to placebo.
KW - Anticoagulant treatment
KW - Disseminated intravascular coagulation
KW - Network meta-analysis
KW - Sepsis
UR - http://www.scopus.com/inward/record.url?scp=85054438230&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054438230&partnerID=8YFLogxK
U2 - 10.1016/j.thromres.2018.10.007
DO - 10.1016/j.thromres.2018.10.007
M3 - Article
C2 - 30312798
AN - SCOPUS:85054438230
SN - 0049-3848
VL - 171
SP - 136
EP - 142
JO - Thrombosis Research
JF - Thrombosis Research
ER -